Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16
InMode Analyst Ratings
InMode Analyst Ratings
Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating
InMode Analyst Ratings
InMode Analyst Ratings
InMode Analyst Ratings
Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)
InMode Analyst Ratings
Barclays Maintains Overweight on InMode, Lowers Price Target to $33
InMode Analyst Ratings
Analysts Offer Insights on Healthcare Companies: InMode (INMD), Ocular Therapeutix (OCUL) and Adverum Biotechnologies (ADVM)
Canaccord Genuity Reiterates Hold on InMode, Maintains $22 Price Target
InMode Analyst Ratings
InMode's Long-Term Potential Overcomes Short-Term Headwinds: A Buy Rating Analysis
UBS Cuts InMode to Neutral, Says Macro Factors Clouding Visibility
Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), Trupanion (TRUP) and Regeneron (REGN)
UBS Downgrades InMode to Neutral, Lowers Price Target to $24
InMode Analyst Ratings
InMode Faces Revenue Headwinds Amid Challenging Economics: Analyst Cuts Price Target And Estimates